Condition (MeSH)
Iliotibial Band Syndrome
ClinicalTrials.gov lists 19 trials for Iliotibial Band Syndrome or a narrower condition beneath it. Hannah Antony has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
19 of the 19 trials are tagged with Iliotibial Band Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Iliotibial Band Syndrome trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2017 | 2 |
| 2015 | 1 |
No forecast is made for this condition: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Iliotibial Band Syndrome trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Not applicable | 18 |
| Observational | 1 |
How many Iliotibial Band Syndrome trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Completed | 11 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Iliotibial Band Syndrome trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Hannah Antony | 1 |
Interventions as named in the registry (2)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Exercise | 1 |
| Traditional therapy | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Iliotibial Band Syndrome? (17)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Conservative treatment of iliotibial band syndrome in runners: Are we targeting the right goals? | Physical therapy in sport : official journal of the Association of Chartered Physiotherapists in Sports Medicine | 2022 | Yes |
| The Iliotibial Band: A Complex Structure with Versatile Functions. | Sports medicine (Auckland, N.Z.) | 2022 | Yes |
| Current Clinical Concepts: Synthesizing the Available Evidence for Improved Clinical Outcomes in Iliotibial Band Impingement Syndrome. | Journal of athletic training | 2021 | Yes |
| Iliotibial band syndrome rehabilitation in female runners: a pilot randomized study. | Journal of orthopaedic surgery and research | 2020 | Yes |
| Relationship between iliotibial band syndrome and hip neuromechanics in women runners. | Gait & posture | 2020 | Yes |
Showing 5 of 17 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.